Inventor
Parsa AKBARI
Inventor
US
Overview
Patents· 5 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms28%
A61KPreparations for medical, dental or toiletry purposes22%
C12NMicroorganisms or enzymes11%
C12YEnzymes6%
G01NInvestigating or analysing materials by determining their chemical or physical properties6%
PatentTitleYear
12,123,001Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors202411,957,704Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors202411,939,635Treatment of obesity in subjects having variant nucleic acid molecules encoding Calcitonin Receptor (CALCR)202411,759,476Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors202311,359,246Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2024Patents assigned to REGENERON PHARMA (5)· patent assignee history
2022Patents assigned to REGENERAN PHARMACEUTICALS INC (1)· patent assignee history
2022–2024Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| REGENERON PHARMA | 5 | 2022–2024 |
| REGENERAN PHARMACEUTICALS INC | 1 | 2022 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 5 | 2022–2024 |